Cancer

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

India and the US are the major manufacturers of finished dosages for the US market in terms of volume (China accounts for 9% of injectables), though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs.

Freenome plans to file for US FDA approval of its blood-based screening test for colorectal cancer mid-year. If cleared, the test would rival Guardant Health’s Shield, the first FDA-cleared blood test for primary screening of colorectal cancer. Exact Sciences is also in the race to bring a blood-based colorectal screening test to market.

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.

The European Medicines Agency is re-evaluating the marketing application for Aplidin. The initial application was rejected in 2018, but that rejection was revoked last year following a court case for another company’s drug that clarified impartiality requirements for experts consulted by the EMA.

Taiho’s acquisition of Swiss next-generation antibody-drug conjugate developer Araris is one of about 10 ADC deals so far in 2025. The companies previously partnered in 2023.

The landscape for overall private biotech financing in 2024 featured investors who were interested in funding new developments – if Big Pharma was willing to pay up eventually in partnerships and M&A – but also reluctance as the industry faced macroeconomic and regulatory uncertainties.